PTPN3 and adrenal cortex carcinoma: In addition, the PFS analysis suggested that PTPN3 serves a risk role in patients with ACC (HR, 2.002; 95% CI 1.198–3.346; p = 0.008), LUSC (HR, 1.443; 95% CI 1.088–1.914; p = 0.011) and UCS (HR, 1.598; 95% CI 1.043–2.446; p = 0.031), while a protective role in patients with KIRC (HR, 0.451; 95% CI 0.363–0.560; p < 0.001), KIRP (HR, 0.645; 95% CI 0.432–0.962; p = 0.032) and UCEC (HR, 0.671; 95% CI 0.532–0.846; p < 0.001) (Fig. 4D).